Physician profile
Meghan B Mccarter
NPI 1740622398
$169,864.30
in general payments reported to CMS, 2019-2025
33 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,390 · 2022: $10K · 2023: $35K · 2024: $62K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Honoraria: $29K · Travel and Lodging: $12K · Food and Beverage: $11K · Consulting Fee: $1,499 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,158.00 |
| Honoraria | $28,760.00 |
| Travel and Lodging | $12,403.21 |
| Food and Beverage | $11,040.98 |
| Consulting Fee | $1,499.00 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $116,089.02 | 2021-2025 | Krystexxa, Evenity, Enbrel |
| Horizon Therapeutics Plc | $40,657.21 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $3,658.47 | 2023-2025 | |
| Abbvie INC. | $2,740.18 | 2021-2025 | |
| Ucb, INC. | $1,141.94 | 2021-2025 | Cimzia, Bimzelx, Nayzilam |
| Janssen Biotech, INC. | $732.88 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $700.90 | 2021-2025 | Taltz, Zepbound |
| Pfizer INC. | $610.48 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $606.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $594.41 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $298.37 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $281.77 | 2022-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $271.42 | 2021-2025 | Lupkynis |
| Organon LLC | $207.42 | 2021-2025 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $172.72 | 2021-2025 | Orencia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $119.32 | 2022-2023 | Tymlos |
| Ani Pharmaceuticals, INC. | $116.58 | 2024-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $108.21 | 2021-2024 | Hyqvia, Cuvitru |
| Fresenius Kabi USA, LLC | $107.84 | 2025 | |
| Sobi, INC | $94.05 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.72 | 2021-2025 | Spevigo |
| Genentech USA, INC. | $84.67 | 2023-2025 | Actemra, Gazyva, Ocrevus Zunovo |
| Biogen, INC. | $67.08 | 2022 | |
| Octapharma USA, INC. | $65.97 | 2024-2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $45.67 | 2022-2025 | Strensiq |
| Pharming Healthcare, INC. | $45.43 | 2023 | Ruconest |
| Scilex Pharmaceuticals INC. | $30.60 | 2024 | |
| Bioventus LLC | $30.23 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $26.41 | 2024 | Arcalyst |
| Invivyd INC | $19.84 | 2025 | Pemgarda |
| Kiniksa Pharmaceuticals, Ltd. | $18.48 | 2023 | Arcalyst |
| Alvogen INC | $16.06 | 2025 | Teriparatide |
| Fidia Pharma USA INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Mccarter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.